Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 8.83B -21.3% |
| Revenue (ttm) | 4.77B +6.0% |
| Net Income | 480.47M +29.3% |
| EPS | 0.56 +31.8% |
| Shares Out | 841.19M |
| PE Ratio | 18.85 |
| Forward PE | 12.12 |
| Dividend | 0.30 (2.82%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | 2,067,973 |
| Open | 1,053.00 |
| Previous Close | 1,049.00 |
| Day's Range | 1,044.50 - 1,057.00 |
| 52-Week Range | 980.40 - 1,426.59 |
| Beta | 0.67 |
| Analysts | Hold |
| Price Target | 1,267.47 (+20.71%) |
| Est. Earnings | Nov 5, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SN stock is "Hold." The 12-month stock price target is 1,267p, which is an increase of 20.71% from the latest price.
News
Smith & Nephew Acquires Xodus Medical to Enhance Product Portfolio
Smith & Nephew Acquires Xodus Medical to Enhance Product Portfolio
Smith & Nephew Launches Cartiheal Agili-C Implant Across Europe, Ticker SNN Updates
Smith & Nephew Launches Cartiheal Agili-C Implant Across Europe, Ticker SNN Updates
Smith & Nephew announces commercial availability of Cartiheal Agili-C in Europe
Smith & Nephew announced that its Cartiheal Agili-C Cartilage Repair Implant is now commercially available in Europe. The Cartiheal Implant will be at this week’s International Cartilage Regeneration ...
Smith+ Nephew's Five-Year Data Supports European Launch Of CARTIHEAL AGILI-C Implant
(RTTNews) - Smith+Nephew (SNN) announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant, an implant designed to repair cartilage damage, restore bone and help relieve...
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CART...
Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización ...
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La tecnologia...
Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CART...
Smith & Nephew PLC's Dividend Analysis
Smith & Nephew PLC's Dividend Analysis
Smith & Nephew removed from European Conviction List at Goldman Sachs
Goldman Sachs analysts removed Smith & Nephew from the firm’s European Conviction List as part of its monthly update.
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith & Nephew receives 510k clearance from FDA, completes cases with LANDMARK
Smith+Nephew announces it received 510(k) clearance from the U.S. Food and Drug Administration, FDA, and has completed the first surgical cases with LANDMARK Total Knee System. “It is truly a…
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Cong...
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Cong...
Smith & Nephew fined £230k after delivery driver seriously hurt
Smith & Nephew Medical has been fined £230,000 after a delivery driver suffered life-changing injuries when a 1.2-tonne crate fell from a forklift truck. The company was found guilty on 12 September o...
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global med...
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global med...
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued
Smith & Nephew price target raised to $33.88 from $33.77 at Berenberg
Berenberg raised the firm’s price target on Smith & Nephew to $33.88 from $33.77 and keeps a Hold rating on the shares.
A Look at Smith & Nephew PLC (SNN) After 3.5% Decline -- GF Value $32.07 vs Price $27.87
A Look at Smith & Nephew PLC (SNN) After 3.5% Decline -- GF Value $32.07 vs Price $27.87
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology ...
Smith & Nephew downgraded to Neutral from Buy at BofA
BofA downgraded Smith & Nephew to Neutral from Buy with a price target of 1,150 GBp, down from 1,340 GBp. FY26 sales growth guidance was lowered at Q2, notes the…